Table 5.
Correlation between polymorphisms and histopathological features of serous and mucinous tumors.
| Non invasive implants (S) | Micropapillary component (S) | Microinvasion (S & M) | Intramucosal carcinoma (M) | |||||
|---|---|---|---|---|---|---|---|---|
| + | − | + | − | + | − | + | − | |
| PHLPP2_L1016S _T3047C | 0/7 (0%) | 5/26 (19%) | 2/6 (33%) | 3/27 (11%) | 1/2 S (50%) 0/2 M (0%) |
4/31 S (13%) 8/16 M (50%) |
2/4 (50%) | 6/14 (43%) |
| ABCB1_G2677T A | 4/7 (57%) | 19/26 (73%) | 5/6 (83%) | 18/27 (67%) | 1/2 S (50%) 1/2 M (50%) |
22/31 S (71%) 12/16 M (75%) |
1/4 (25%) | 12/14 (86%) |
| FGFR2_rs2981582_CT | 3/7 (43%) | 15/26 (58%) | 4/6 (66%) | 13/27 (48%) | 1/2 S (50%) 2/2 M (100%) |
17/31 S (55%) 9/16 M (56%) |
3/4 (75%) | 8/14 (57%) |
| VEGF_5_1154_A_ref | 1/7 (14%) | 12/26 (46%) | 2/6 (33%) | 11/27 (41%) | 1/2 S (50%) 1/2 M (50%) |
12/31 S (39%) 8/16 M (50%) |
2/4 (50%) | 7/14 (50%) |
| VEGF_5_1498_CT | 6/7 (86%) | 20/26 (77%) | 5/6 (83%) | 21/27 (78%) | 2/2 S (100%) 2/2 M (100%) |
24/31 S (77%) 10/16 M (62%) |
3/4 (75%) | 9/14 (64%) |
| VEGF_5_2573_CA | 1/7 (14%) | 6/26 (23%) | 1/6 (17%) | 6/27 (22%) | 2/2 S **(100%) 0/2 M (0%) |
5/31 S **(16%) 1/16 M (6.2%) |
0/4 (0%) | 1/14 (7%) |
| VEGF_5_634_GC_ref | 5/7 (71%) | 18/26 | 4/6 (66%) | 19/27 (70%) | 2/2 S (100%) 0/2 M |
21/31 S 9/16 M |
3/4 (75%) | 6/14 (43%) |
(S) = serous; (M) = mucinous